Featured Research

from universities, journals, and other organizations

New Protease Inhibitor Could Thwart AIDS Resistance To Current Drugs

Date:
February 4, 1999
Source:
American Chemical Society
Summary:
Researchers have developed a new protease inhibitor effective against mutating strains of the human AIDS virus that are resistant to current drugs, according to a just-released report in the peer-reviewed Journal of the American Chemical Society.

Researchers have developed a new protease inhibitor effective against mutating strains of the human AIDS virus that are resistant to current drugs, according to a just-released report in the peer-reviewed Journal of the American Chemical Society.

The paper will be published on the web on Feb. 4 and will be in the journal's Feb. 17 print edition. The American Chemical Society is the world's largest scientific society.

Most AIDS drugs disable the human immunodeficiency virus (HIV) by latching onto an enzyme, such as a protease, that the virus needs to multiply. However, HIV quickly mutates and becomes resistant to individual inhibitors within weeks.

The most successful treatment to date tries to overwhelm HIV with two or three of these drugs simultaneously in a so-called "combination therapy," but even this approach eventually loses effectiveness.

Researchers at The Scripps Research Institute in La Jolla, Calif. think they now know how HIV adapts so readily to the current treatments. Over time, HIV proteases apparently change structure so that the inhibitors can no longer bind tightly. "We have studied the mutation pattern of HIV protease from patients who take the existing drugs and found that the enzyme often rejects the drug by reducing the size of the drug binding site," says Scripps chemist Chi-Huey Wong, Ph.D.

The scientists then looked at the corresponding binding site on current HIV protease inhibitors and found that most of them have large chemical structures that interact with the constricted areas in drug-resistant proteases. So they redesigned the drugs, giving them a smaller chemical group at the critical binding site. In laboratory tests, the new class of inhibitors was effective against both HIV protease and its drug-resistant mutants. "More importantly," adds Wong, "no resistant mutants were detected in cell culture after one year the new drug may last longer as the chance for development of drug resistance is lower."

The same chemical may also become the first treatment for feline AIDS, a significant threat to the world cat population. Coincidentally, the virus causing the cat version of AIDS (feline immunodeficiency virus, or FIV) uses a protease that has a naturally small binding site and thus resembles many drug- resistant HIV proteases.

###

A nonprofit organization with a membership of nearly 159,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "New Protease Inhibitor Could Thwart AIDS Resistance To Current Drugs." ScienceDaily. ScienceDaily, 4 February 1999. <www.sciencedaily.com/releases/1999/02/990204082547.htm>.
American Chemical Society. (1999, February 4). New Protease Inhibitor Could Thwart AIDS Resistance To Current Drugs. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/1999/02/990204082547.htm
American Chemical Society. "New Protease Inhibitor Could Thwart AIDS Resistance To Current Drugs." ScienceDaily. www.sciencedaily.com/releases/1999/02/990204082547.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com
House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Uganda on Alert for Ebola but No Confirmed Cases

Uganda on Alert for Ebola but No Confirmed Cases

AFP (July 31, 2014) Uganda's health minister said on Thursday that there are no confirmed cases of Ebola in the country, but that it remained on alert for cases of the deadly virus. Uganda has suffered Ebola outbreaks in the past, most recently in 2012. Duration: 00:59 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins